Evaluating Novel Target Trial Data, Isotope Selection, Dosimetry Assessment, & Share Regulatory Insights to Drive & Achieve RLT Potential as First-Line & Combination Therapies in Modern Oncology
Targeted radiopharmaceuticals have entered a new era. Clinical success is accelerating investment, pipelines are rapidly expanding beyond lutetium into next-generation alpha emitters and novel targets, and developers are racing to bring transformative radioligand therapies to patients. As the field matures, the industry's greatest challenges involve clinical translation, isotope availability, manufacturing scale-up and regulatory alignment.
The 8th Targeted Radiopharmaceuticals Summit Europe unites the scientific, clinical, manufacturing, regulatory and commercial leaders driving this transformation to build the blueprint for Europe's next generation of targeted radiopharmaceuticals.
Join your peers to:
Advance Next-Generation Radiopharmaceutical Innovation
Discover the latest breakthroughs across novel targets, alpha emitters, Auger therapies and next-generation radiopharmaceutical platforms to strengthen your discovery and preclinical strategy.
Accelerate Clinical Translation
Learn how leading developers are optimising trial design, dosimetry, combination strategies and earlier-line treatment approaches to generate stronger clinical evidence and maximise patient impact.
Build Resilient Manufacturing & Supply Strategies
Overcome isotope availability, GMP manufacturing, automation, logistics and supply chain bottlenecks to support scalable clinical development and future commercial success.
Navigate Europe's Evolving Regulatory Landscape
Hear directly from MHRA, Swissmedic, the IAEA and the Office for Nuclear Regulation to understand the latest regulatory expectations and accelerate European clinical and commercial development.
Benchmark Against Europe's Leading TRP Community
Connect with 50+ expert speakers, including 18 C-level executives, 8 global pharma companies, 4 regulatory organisations, 5 leading clinical centres and 200+ senior industry leaders, to exchange practical strategies and build valuable new partnerships.
This is your opportunity to join Europe's most comprehensive, end-to-end forum dedicated to targeted radiopharmaceutical development, where discovery, clinical translation, manufacturing, regulation and commercial strategy come together to accelerate the next generation of radioligand therapies from discovery to patients.
-
“I thoroughly enjoyed the panel of experts, as their insights during the workshop and the summit were truly enriching. The quality of the talks was exceptional, and the summit's format fostered meaningful connections and engaging discussions with fellow attendees.”
Co-Founder & Chief Executive Officer, Aken Medical
-
“Excellent balance of interesting program content and ample time for networking.”
Chief Scientific Officer & Vice President, Research, Affibody AB
-
“Great and broad content. The smaller format enabling easy networking and meeting "all".”
Senior Director, Targeted Radiopharmaceuticals, Bayer
Explore the Full Event Guide
- Brand-New Interactive Workshops & Seminars
- 15+ Exclusive Clinical Readouts & Real-World Case Studies
- Europe's Strongest Regulatory Faculty (MHRA, Swissmedic, IAEA & ONR)
- The Great Isotope Debate
- 20+ Hours of Curated Networking, Including Meet & Match Partnering
- 50+ World-Class Speakers from Across the TRP Ecosystem
- Europe's Most Comprehensive End-to-End Forum Dedicated to Targeted Radiopharmaceutical Development
Official Partners
Attending Companies Include
Explore the Agenda
Discover the scientific, clinical and commercial strategies that will become your blueprint for accelerating targeted radiopharmaceuticals from discovery to patients.
Partner With Us
Showcase your technologies and services to 200+ senior decision-makers actively seeking CROs, CDMOs, isotope suppliers, radiopharmacies, dosimetry providers and specialist partners to advance the next generation of radiopharmaceuticals.
Join Europe's TRP Leaders:
Be part of Europe's most comprehensive targeted radiopharmaceuticals forum, uniting pharma, biotech, regulators, clinical centres, investors and solution providers to shape the future of radioligand therapy.